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Despite great advances in antiretroviral therapy (ART) in
the last decade, several limitations remain regarding
adverse effects, poor adherence, and drug-drug interac-
tions. Switching ART in stable, virologically suppressed
patients with the aim of improving tolerability and conve-
nience is a widely used strategy in clinical practice. Several
factors need to be considered when switching from a suc-
cessful antiretroviral regimen, including previous virologic
failure and duration of virologic suppression, genetic bar-
riers to resistance of the new regimen and expected level
of adherence. Reductions in the number of pills, drugs, or
doses are the most common switching strategies.
Triple therapy regimens including ritonavir-boosted
protease inhibitors (PI/r) are the most frequently
switched regimens. Thymidine analogues, which are now
uncommon in developed countries, have been success-
fully replaced with non-thymidine analogues in recent
years. The main aim of this switch is to prevent or
improve abnormal fat redistribution.
Simple one-pill triple regimens such as tenofovir/emtri-
citabine (TDF/FTC) plus efavirenz (EFV), rilpivirine (RPV)
or Elvitegravir/Cobicistat (ELVI/Cobi) may help to
improve adherence and reduce some PI/r toxicities. The
use of PI/r monotherapy is accepted in EACS Guidelines
for selected virologically suppressed patients and may be
an option for patients with previous nucleoside analogue
toxicities, such as tenofovir-related nephrotoxicity. Ralte-
gravir may be switched to once-daily regimens to improve
adherence or it may replace other drugs to avoid interac-
tions in medically complex patients. Unboosted atazanavir
is a PI-containing option for patients who do not tolerate
ritonavir. Two drug regimens have been assessed in rando-
mized clinical trials and cohort studies with different
results because of negative drug interactions leading to
unexpected toxicities or low efficacy in some cases.
In summary, many switching options are currently
available for virologically suppressed patients. However,
although switching strategies may be useful for improv-
ing ART, not all regimens used in clinical practice are
based on data from randomized clinical trials and not
all regimens are suitable for everyone. It is therefore
important to individualize treatment, taking into consid-
eration not only patient and drug characteristics but
also the best evidence available.
Published: 23 May 2014
doi:10.1186/1471-2334-14-S2-S4
Cite this article as: Podzamczer: Switch strategies in 2014. BMC Infectious
Diseases 2014 14(Suppl 2):S4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitHIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge,
L’Hospitalet, 08907, Barcelona, Spain
Podzamczer BMC Infectious Diseases 2014, 14(Suppl 2):S4
http://www.biomedcentral.com/1471-2334/14/S2/S4
© 2014 Podzamczer; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
